Tim is CEO and member of the Board of Directors of Agomab, a Belgian biotech company focusing on growth factor biology and developing therapeutics for fibrotic indications. Together with the team, he has raised around $140M from top US and EU investors since joining Agomab in 2019. Prior to Agomab, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial in patients with acute kidney injury, secured an option-to-buy deal with Pfizer and raised significant private financing rounds. Prior to that, Tim was a Senior Associate at Aescap Venture, a VC fund investing in European medical companies. Tim is a Henri Termeer Fellow and was selected as an Endpoints 20 under 40 and In Vivo rising leader. He holds an executive MBA from IMD, where he was named Valedictorian, and earned two Master degree programs from Utrecht University.